GlassScriptPhysician profile
Nicholas G Ciminera
NPI 1972095255
$3,185.59
in general payments reported to CMS, 2019-2025
24 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $349 · 2023: $503 · 2024: $807 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Travel and Lodging: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.51 |
| Travel and Lodging | $376.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,276.71 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Heartmate Touch |
| Kestra Medical Technology Services, INC. | $363.81 | 2024-2025 | Assure Wcd |
| La Jolla Pharmaceutical Company | $223.55 | 2021-2025 | Giapreza |
| Merck Sharp & Dohme LLC | $200.91 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $175.94 | 2023-2025 | |
| Cvrx, INC. | $150.75 | 2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $128.43 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $113.80 | 2024-2025 | Wainua |
| Abiomed | $104.07 | 2023 | Impella |
| Livanova USA, INC. | $63.52 | 2022 | |
| Pfizer INC. | $61.14 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $40.67 | 2025 | Onpattro |
| Edwards Lifesciences Corporation | $39.96 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $39.77 | 2022 | |
| Teleflex LLC | $36.94 | 2024 | Manta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $29.40 | 2024 | Telepatch Cardiac Monitor |
| Akcea Therapeutics, INC. | $19.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.92 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $18.52 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.28 | 2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $16.23 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.26 | 2025 | Lifevest |
| Hologic Sales and Service, LLC | $14.87 | 2024 | Myosure Tissue Removal Device |
| Lexicon Pharmaceuticals, INC. | $14.41 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ciminera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.